ALK Abello reports positive financials for third quarter with sales up 3%
Denmark-based allergy specialist ALK Abello (ALKB: DC) has reported positive results for the third quarter of 2014.
Sales grew to 522 million Danish kroner ($87 million), an increase of 3% from 509 million kroner in the same quarter last year. Earnings before interest, tax, depreciation and amortization before special items was 57 million kroner, up from 54 million kroner in the third quarter of 2013. Earnings per share likewise increased, now standing at 17.1 kroner, up from 2.2 kroner last year.
ALK’s full-year outlook remains unchanged, with revenue expected to be approximately 2.4 billion kroner. EBITDA before special items is forecast at 450 million kroner.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze